Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.141 | Quantification of erosion, joint space width and new bone formation using deep learning-based approaches |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.128 | Portable integrated diagnostic platform for chronic auto-immune diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.401 | Immunological role of the ILC2-B lymphocyte regulatory axis in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.530 | 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.063 | Effects of tight-control strategy with rosuvastatin on progression of subclinical carotid and coronary atherosclerosis in psoriatic arthritis- a prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2018.144 | Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.247 | Survival benefit of statin use in patients with immune mediated inflammatory diseases in Hong Kong - A population-based study | Prof. TAM Lai Shan |
| 2020.129 | Vascular effects of achieving low disease activity in axial spondyloarthritis - a 2-year prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.180 | The microbiome study in psoriasis and psoriatic arthropathy patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.224 | Effects of achieving SDAI remission on joint space outcomes progression in early rheumatoid arthritis: an HR-pQCT study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.573 | Subclinical gut inflammation and gut microbiome in axial spondyloarthritis patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.617 | Subclinical atherosclerosis in axial spondyloarthritis- a cross-sectional study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.519 | Cardiovascular events in axial spondyloarthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.225 | The APLAR Spondyloarthritis (SpA) Registry |
Prof. TAM Lai Shan 譚麗珊 |
| 2024.718 | REMIPPSA: REMISSION STATUS IN PSORIATIC ARTHRITIS FROM THE PATIENT’S PERSPECTIVE. A QUALITATIVE STUDY. | Prof. TAM Lai Shan |
| 2024.661 | Methotrexate versus TNF inhibition in preventing structural damage in Early Psoriatic Arthritis: A randomized trial using HR-pQCT (MeTEPsA trial) | Prof. TAM Lai Shan |
| 2024.352 | A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout |
Prof. TAM Lai Shan 譚麗珊 |
| 2025.019 | Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2024.221 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2024.193 | Lowest Efficacious Dose in Psoriatic Arthritis (LED PsA): A Multicentre Non-inferiority Randomized Open-Label Controlled Trial Assessing b/tsDMARDs Spacing | Prof. TAM Lai Shan |
| 2024.182 | Causal machine learning models for prediction of serious infection events in inflammatory arthritis: a population-based study |
Prof Tam Lai Shan Lai Shan TAM |
| 2025.008 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2021.460 | Profiling of Serum Protein Biomarkers in Psoriatic Arthritis–Associated Disease Activity Assessment and Bone Damage |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.127 | Machine learning models to quantify and predict radiographic joint damage in rheumatoid arthritis |
Prof. TAM Lai Shan Lai Shan TAM |
| 2023.051 | Discovering new post-translational modification patterns for the early diagnosis of rheumatoid arthritis | Prof. TAM Lai Shan |
| 2023.181 | Anti-inflammatory mechanisms of immune-adipose-related Meteorin-like protein (METRNL) in Systemic Lupus Erythematosus | Dr. TAM Lai Shan |
| 2022.686 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with psoriatic arthritis | Prof. TAM Lai Shan |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.343 | AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS COHORT (AXIS) a joint ASAS-GRAPPA project |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.306 | Low-dose computed tomography for the detection of structural changes in axial psoriatic arthritis | Prof. TAM Lai Shan |
| 2021.315 | Axial involvement in patients with Psoriatic Arthritis in Hong Kong – a cross-sectional pilot study |
Prof TAM Lai Shan 譚麗珊 |
| 2023.317 | Early identification of axial psoriatic arthritis among patients with psoriasis: a screening study using low-dose computed tomography | Prof. TAM Lai Shan |
| 2023.355 | Sex- And Gender-based analysis of the Effectiveness of advanced therapies in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.401 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2023.633 | Defining active and structural lesions in the sacroiliac joint and spine by MRI and their predictive utility in axial psoriatic arthritis -a prospective study | Prof Tam Lai Shan |
| 2021.706 | Effect of Achieving Minimal Disease on the Progression of Subclinical Coronary Atherosclerosis: A Citywide Prospective Cohort Study in Psoriatic Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2022.151 | Osteosarcopenia Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and fracture risk in non-osteoporotic patients with immune-mediated inflammatory disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2012.082 | Periatricular and generalized bone loss in psoriatic arthritis | Prof. Tam Lai-Shan |
| 2011.558 | RAGE: a new therapeutic target and biomarker of rheumatoid arthritis | Professor Tam Lai-Shan |
| 2011.209 | Assessment of PROMIS Fatigue Bank with SLE-specfic items for use in an Asian SLE population in Hong Kong and Singapore | Prof. TAM Lai-Shan |
| 2011.174 | A stochastic cost-effectiveness analysis of an early inflammatory arthritis clinic in Hong Kong | Prof. TAM Lai-Shan |
| 2011.276 | Ankylosing spondylitis vascular study | Prof. TAM Lai-Shan |
| 2009.273 | Diagnostic and Prognostic Values of Anti-Ceclic Citullinated Peptide Antibodies in Chinese Population with Rheumatoid Arthritis | Prof. Tam Lai-Shan |
| 2009.409 | Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study | Prof Tam Lai-Shan |
| 2009.429 | A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Dr. TAM Lai-Shan |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2011.050 | A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A-623 Administration in Subjects with Systemic Lupus Erythematosus | Professor Tam Lai-Shan |
Page 201 of 262.